Search - tctmd.com

Displaying 61 - 80 of 305

Sort: Relevancy | Date

Presentation TCT 2021

Introduction to case: Zero contrast PCI in the RCA for an ACS patient with MVD

Presenter: Allen Jeremias

November 04, 2021

Presentation TVT 2021

Complete 2-year Follow-Up from Evolut Low Risk Trial

Presenter: John Forrest

July 20, 2021

Presentation TVT 2021

TAVR and SAVR “Sequencing”: Lifelong Management Journey of Severe AS

Presenter: Isaac George

July 20, 2021

Presentation TVT 2021

Choosing the First TAVR Prosthesis: Self Expanding vs Balloon Expandable – Advantages and Disadvantages

Presenter: Uri Landes

July 20, 2021

Presentation TVT 2021

Clinical and Anatomic Considerations for TAVR in a Young Patient (<65 yo): Durability, Coronary Access, and More

Presenter: Gilbert Tang

July 20, 2021

Presentation TVT 2021

The PARTNER 3 Bicuspid Registry for SAPIEN 3 Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk

Presenter: Mathew Williams

July 20, 2021

Presentation TVT 2021

Comparison of 1-Year Outcomes After Transcatheter Aortic Valve Replacement in Low-Risk Patients With Severe Bicuspid and Tricuspid Aortic Valve Stenosis

Presenter: John Forrest

July 20, 2021

Presentation TCT 2020

OPTIMIZE: A Randomized Trial of a Novel, Ultra Low Profile Fixed-Wire DES

Presenter: Dean Kereiakes

October 17, 2020

Presentation TCT 2020

TAVR in Low Surgical Risk Patients - Intervention (Surgery or TAVR) in Severe Asymptomatic Aortic Stenosis: Evidence Updates

Presenter: Philippe Genereux

October 16, 2020

Presentation TCT 2020

TAVR in Low Surgical Risk Patients - Evidence Updates From Evolut Low-Risk

Presenter: Michael Reardon

October 16, 2020

Presentation TCT 2020

TAVR in Low Surgical Risk Patients - Evidence Updates From PARTNER 3

Presenter: Martin Leon

October 16, 2020

Presentation TCT 2020

TCT 465: Implantation Characteristics and Development of Hypoattenuated Leaflet Thickening in Low Risk Patients undergoing Transcatheter Aortic Valve Replacement

Presenter: Jaffar Khan

October 14, 2020

Presentation TCT 2020

TCT 281: Clinical Outcomes of Optical Coherence Tomography Detected High Risk Versus Low Risk Coronary Atherosclerotic Lesions in Medically Treated Fractional Flow Reserve Negative Lesions in Diabetes Mellitus Patients. The COMBINE Trial.

Presenter: Elvin Kedhi

October 14, 2020

Presentation TCT 2020

TCT 147: Limitations of Established Cardiac Biomarkers in Low- to Intermediate-Risk TF-TAVR Patients With Advanced CKD

Presenter: Hatim Seoudy

October 14, 2020

Presentation TVT 2020

Transcatheter Aortic Valve Replacement using an Evolut PRO Bioprosthesis in Low Risk Patients with Aortic Stenosis

Presenter: Bruce Rutkin

June 20, 2020

Presentation JIM 2020

Ultra LOW LDL is the target for high risk patients

Presenter: Francesco Prati

February 13, 2020

Presentation JIM 2020

Long term antithrombotic therapy in high risk PCI: Consider low-dose rivaroxaban with SAPT

Presenter: Giuseppe Tarantini

February 13, 2020

Presentation Live Valves 2019

All Trileaflet AS (even low risk) Should be Treated with TAVI

Presenter: Vinod H. Thourani

December 10, 2019

Presentation Live Valves 2019

All AS Patients ( incl. Low-Risk) should be treated with TAVI

Presenter: Christian W. Hamm

December 10, 2019

Presentation CACI 2019

TAVI in Low Risk Patients

Presenter: Fayaz Shawl

November 29, 2019

Advertisement

Introduction to case: Zero contrast PCI in the RCA for an ACS patient with MVD

Complete 2-year Follow-Up from Evolut Low Risk Trial

TAVR and SAVR “Sequencing”: Lifelong Management Journey of Severe AS

Choosing the First TAVR Prosthesis: Self Expanding vs Balloon Expandable – Advantages and Disadvantages

Clinical and Anatomic Considerations for TAVR in a Young Patient (<65 yo): Durability, Coronary Access, and More

The PARTNER 3 Bicuspid Registry for SAPIEN 3 Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk

Comparison of 1-Year Outcomes After Transcatheter Aortic Valve Replacement in Low-Risk Patients With Severe Bicuspid and Tricuspid Aortic Valve Stenosis

OPTIMIZE: A Randomized Trial of a Novel, Ultra Low Profile Fixed-Wire DES

TAVR in Low Surgical Risk Patients - Intervention (Surgery or TAVR) in Severe Asymptomatic Aortic Stenosis: Evidence Updates

TAVR in Low Surgical Risk Patients - Evidence Updates From Evolut Low-Risk

TAVR in Low Surgical Risk Patients - Evidence Updates From PARTNER 3

TCT 465: Implantation Characteristics and Development of Hypoattenuated Leaflet Thickening in Low Risk Patients undergoing Transcatheter Aortic Valve Replacement

TCT 281: Clinical Outcomes of Optical Coherence Tomography Detected High Risk Versus Low Risk Coronary Atherosclerotic Lesions in Medically Treated Fractional Flow Reserve Negative Lesions in Diabetes Mellitus Patients. The COMBINE Trial.

TCT 147: Limitations of Established Cardiac Biomarkers in Low- to Intermediate-Risk TF-TAVR Patients With Advanced CKD

Transcatheter Aortic Valve Replacement using an Evolut PRO Bioprosthesis in Low Risk Patients with Aortic Stenosis

Ultra LOW LDL is the target for high risk patients

Long term antithrombotic therapy in high risk PCI: Consider low-dose rivaroxaban with SAPT

All Trileaflet AS (even low risk) Should be Treated with TAVI

All AS Patients ( incl. Low-Risk) should be treated with TAVI

TAVI in Low Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content